Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06951880 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT06951880 is a Phase 1 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 160 participants.
The verdict
NCT06951880, a Phase 1 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.
Interventions
- OTHER Placebo
- DRUG AZD4916
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-07-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06951880
The ClinicalTrials.gov registry entry for NCT06951880 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06951880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06951880 about?
NCT06951880 is a clinical study titled "A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers". The main purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) of AZD4916 in healthy adult participants.
What is the current status of trial NCT06951880?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-07-23. Estimated completion is 2027-10-25.
What interventions are being tested in trial NCT06951880?
The interventions under investigation include: Placebo (OTHER), AZD4916 (DRUG).
Who is sponsoring clinical trial NCT06951880?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.